ReviewInternational journal of molecular medicine2026
Roles of ubiquitin‑specific peptidase 22 in cellular fate: From embryonic survival to tissue repair, inflammation and metabolism (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitin‑specific peptidase 22 (USP22), a key member of the deubiquitinase family, serves pivotal roles in tumorigenesis by driving tumor proliferation, metastasis and drug resistance. In addition to its role in oncology, its versatile functions in diverse physiological and pathological contexts have been revealed. These include ensuring embryonic viability through developmental signaling regulation, promoting tissue repair and contributing to ischemia‑reperfusion injury, inflammatory responses and immune activation via cytokine and immune cell regulation. USP22 is also involved in fibrosis, metabolic homeostasis and tissue remodeling in patients with conditions such as asthma and pneumoconiosis. These multifaceted actions are mediated primarily through the deubiquitination of target proteins such as silent mating‑type information regulation 2 homologue 1 and through epigenetic mechanisms, including histone modification. The present review summarized recent advances in USP22‑mediated cell fate regulation and evaluates its therapeutic potential across diseases, underscoring promising prospects for clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.